ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.

Christine M LovlyPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.